Compare GSBC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | IOVA |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 968.6M |
| IPO Year | N/A | N/A |
| Metric | GSBC | IOVA |
|---|---|---|
| Price | $64.13 | $2.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $59.50 | $10.45 |
| AVG Volume (30 Days) | 60.5K | ★ 11.3M |
| Earning Date | 01-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 18.31 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | $228,683,000.00 | ★ $250,425,000.00 |
| Revenue This Year | N/A | $60.94 |
| Revenue Next Year | N/A | $60.85 |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | 7.86 | ★ 175.62 |
| 52 Week Low | $47.58 | $1.64 |
| 52 Week High | $66.59 | $8.15 |
| Indicator | GSBC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.18 | 58.51 |
| Support Level | $65.08 | $2.08 |
| Resistance Level | $66.59 | $2.60 |
| Average True Range (ATR) | 1.24 | 0.14 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 63.58 | 77.88 |
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.